New diabetes pill shows promise in year-long safety trial
NCT ID NCT02314637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the long-term safety and blood sugar control of the drug MP-513 (Teneligliptin) in 240 Japanese adults with type 2 diabetes. Some participants took MP-513 alone, while others took it together with another diabetes medicine called glimepiride. The study lasted 52 weeks and tracked side effects and changes in blood sugar levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Reserch site
Shikoku, Japan